MedWatch

Ambu's stock hits lowest price in five years

An analyst from Carnegie says there are several factors explaining why the medtech firm’s share price has declined to a level not seen since 2017.

Photo: PR / Ambu

Ambu has been facing headwinds on the stock exchange in recent days, and Head of Equity Research at Carnegie Investment Bank Niels Granholm-Leth has identified several potential factors as to why.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs